期刊文献+

可溶性ST2联合NT-proBNP评估射血分数保留性心力衰竭患者的短期预后价值 被引量:8

Short-term prognostic value of soluble ST2 and NT-pro BNP in patients with heart failure with preserved ejection fraction
下载PDF
导出
摘要 目的评估可溶性ST2(soluble ST2,sST2)联合血浆氨基末端脑钠肽前体(N-terminal pro-brain natriureticpeptide,NT-proBNP)对射血分数保留性心力衰竭(heart failure with preserved ejection fraction,HFPEF)患者短期预后的临床预测价值。方法选择128例深圳市光明新区人民医院住院的HFPEF患者,依据随访1年预后结局差异分为:研究组,共65例,随访1年发生主要心血管事件(major adverse cardiovascular events,MACE);对照组,共63例,随访1年未发生MACE。检测并比较两组的sST2、NT-proBNP、总胆固醇(total cholesterol,TC),低密度脂蛋白胆固醇(low density lipoprotein-cholesterol,LDL-C)以及糖化血红蛋白(glycosylated hemoglobin,HbA_1c)浓度;应用超声心动图检测并比较两组左心室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张末期内径(left ventricular end diastolic diameter,LVEDd)、E/A比值差异。应用单因素直线分析及多元Logistic回归分析对患者MACE发生率相关的危险因素进行分析,应用受试者工作特征(receiver operator char-acteristic,ROC)曲线分析sST2联合NT-proBNP的最佳预测值。结果与对照组相比,研究组的sST2、NT-proBNP、LVEDd显著较高,E/A比值明显降低,差异有统计学意义(P<0.05);而两组LVEF及HbA_1c、TC、LDL-C浓度比较,差异无统计学意义(均P>0.05)。单因素直线分析显示sST2、NT-proBNP、LVEDd、E/A比值与MACE发生率相关,多元Logistic回归分析显示sST2、NT-proBNP为MACE的独立预测因子。ROC曲线分析显示,血浆sST2≤1 505pg/m L与NT-proBNP≤3010pg/mL为预测MACE发生的最佳预测切点(曲线下面积分别为0.823、0.789,P值分别为0.026、0.017)。结论 sST2联合NT-proBNP能较好预测HFPEF患者的短期预后。 Objectives To analyze the short-term prognostic value of soluble ST2(sST2)and N-terminal pro-brainnatriuretic peptide(NT-proBNP)in patients with heart failure with preserved ejection fraction(HFPEF). Methods Totally 128 patients with HFPEF in Shenzhen Guangming New District People′s Hospital were collected to retrospectivelystudy and divided into two groups according to prognostic outcome of one year follow-up,which were research group[65 cases,complicated with major adverse cardiovascular events(MACE)]and control group(63 cases,not compli-cated with MACE). sST2,NT-pro BNP,total cholesterol(TC),low density lipoprotein-cholesterol(LDL-C)and glyco-sylated hemoglobin(HbA_1c)were detected and compared between the two groups. Left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDd) and E/A ratio were detected by ultrasonic cardiogram(UCG)and compared between the two groups. The relative risk factors to the occurrence of MACE were confirmed bysingle-factor linear analysis and multivariate Logistic analysis. The best cut-off points of sST2 and NT-proBNP wereconfirmed by the area under curve(AUC)of the receiver operator characteristic(ROC)curve. Results Compared tocontrol group,sST2,NT-proBNP and LVEDd of research group were significantly higher,and E/A ratio of researchgroup was lower(P〈0.05),but LVEF,TC,LDL-C and Hb A1 cbetween the two groups had no significantly differences(P〉0.05). Single-factor linear analysis indicated that sST2,NT-proBNP,LVEDd and E/A ratio relatived to occur-rence of MACE. Multivariant Logistic analysis showed that sST2 and NT-pro BNP were independent risk factors for occur-rence of MACE. Plasma concentrations of sST2≤1505pg/m L and NT-pro BNP≤3010pg/m L were the best predictedpoints to occurrence of MACE(AUC=0.823,0.789;P=0.026,0.017). Conclusions Plasma concentrations of sST2 and NT-proBNP can predict the short-term prognosis of patients with HFPEF.
作者 李吉博 安娜 王佳 刘志勇 赵春光 LI Ji-bo;AN-Na;WANG-Jia;LIU Zhi-yong;ZHAO Chun-guang(Department of ICU, Shenzhen Guangming New District People' s Hospital, Shenzhen, Guandong 518106, China;Department of Emergency, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Urumqi 834000, China;Department of Severe Medicine, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China;Department of Severe Medicine, Xiangya Hospital of Central South University, Changsha 410008, China)
出处 《岭南心血管病杂志》 2018年第2期193-196,227,共5页 South China Journal of Cardiovascular Diseases
关键词 心力衰竭 可溶性ST2 N末端脑钠肽前体 预后 heart failure soluble ST2 N-ternfinal pro-brain natriuretic peptide prognosis
  • 相关文献

参考文献1

二级参考文献22

  • 1Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST- segment elevation myocardial infarction. J Am Coll Cardiol 2000; 36: 970-1062.
  • 2Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and Regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106: 2961-2966.
  • 3Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, et al. Serum levels of the interleukin- 1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004; 109: 2186-2190.
  • 4Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial Infarction. Circulation 2008; 117: 1936-1944.
  • 5Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, Ng LL. Interleukin 33 and ST2 in non-ST elevation myocardial infarction: Comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 2011; 61:1163-1170.
  • 6Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardio12010; 55: 243-250.
  • 7Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, et al. ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 2010; 159: 788- 794.
  • 8Granger CB, Goldberg R J, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2006;163: 2345-2353.
  • 9Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1 like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479- 490.
  • 10Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 innon-st-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012; 58: 257-266.

共引文献26

同被引文献64

引证文献8

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部